CTOs on the Move

Plexium

www.plexium.com

 
Plexium is the premier, next-generation Targeted Protein Degradation (TPD) company seeking to discover a wide range of monovalent target protein degraders that address the limitations of heterobifunctional degraders and cereblon IMiDs. The company is powered by its proprietary drug discovery platform designed to identify novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated proteasomal degradation. From molecular glues to monovalent degraders, Plexium is advancing a pipeline of novel targeted protein degraders for the treatment of cancer, neurodegeneration, and other diseases. Due to its expertise in TPD, Plexium has entered into strategic collaborations with Amgen ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.plexium.com
  • 11494 Sorrento Valley Road
    San Diego, CA USA 92121
  • Phone: 858.263.7491

Executives

Name Title Contact Details
Daniel Sipes
Senior Vice President and Head of Technology Profile

Funding

Plexium raised $28M on 10/17/2019
Plexium raised $35M on 01/19/2021

Similar Companies

Enzo

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem`s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

CODA Biotherapeutics

CODA Biotherapeutics` revolutionary chemogenetic platform aims to control the activity of cells to treat disease. With chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable `switch` protein. Cells modified with the `switch` can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells.

AxxiTrials

AxxiTrials is a Irvington, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NextCure

NextCure is a fully integrated biotechnology company discovering and developing first-in-class immunotherapy-based biologics for cancer and other diseases. The company is focused on understanding biological pathways and leveraging our FIND-IOTM technology to discover, validate and build a proprietary pipeline. We believe identifying and targeting immune pathways will promote identification of effective targets for mediating sustained immunity leading to improved outcomes for cancer patients.

EduQuest

EduQuest is a Clarksburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.